Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells

Anti-Cancer Drugs

Volumn 24, Issue 2, 2013, Pages 120-130

  Lattanzio, Laura ^a   Tonissi, Federica ^a   Monteverde, Martino ^a   Milano, Gerard ^b   Merlano, Marco C ^a   Lo Nigro, Cristiana ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

docetaxel; octreotide; PC3 cell line; prostate cancer; somatostatin receptor

Indexed keywords

ANGIOPEPTIN; CASPASE 3; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN 1; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN FUNCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; MALE; OCTREOTIDE; P-GLYCOPROTEIN; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TAXOIDS;

EID: 84873203101     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328358d1dc     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. Cancer J Clin 2008; 58:71-96
2. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progressionfree survival as a predictor of overall survival in men with castrate-resistant prostate. Cancer J Clin Oncol 2009; 27:2766-2771
3. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, et al. ERK inhibitor PD98059 enhances docetaxel-Induced apoptosis of androgen-Independent human prostate cancer cells. Int J Cancer 2003; 107:478-485
4. Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, et al. Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer 2007; 96:269-276
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512
6. Paller CJ, Antonarakis ES. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011; 5:117-124
7. Rehman Y, Rosenberg JE. Abiraterone acetate: Oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug Des Devel Ther 2012; 6:13-18
8. Seidman R, Gitelman I, Sagi O, Horwitz SB,Wolfson M. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-Induced apoptosis in human ovarian carcinoma cells. Exp Cell Res 2001; 268:84-92
9. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002; 23:1831-1838
10. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57:229-233
11. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: Much ado about nothing? Ann Oncol 2002; 13:653-668
12. Tejeda M, Gaal D, Hullan L, Hegymegi-Barakonyi B, Keri GY. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models. Anticancer Res 2006; 26:3477-3484
13. Ruscica M, Arvigo M, Gatto F, Dozio E, Feltrin D, Culler MD, et al. Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol Cell Endocrinol 2010; 315:254-262
14. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010; 16:2963-2970
15. Olias G, Viollet C, Kusserow H, Epelbam J, Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem 2004; 89:1057-1091
16. Cariga-Martinez AE, Lorenzati MA, Riera MA, Cubilla MA, De La Rossa A, Giorgio EM, et al. Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. Adv Urol 2009; 723831:1-8
17. Marbach P, Briner U, Lemaire M, Schweizer A, Terasaki T. From somatostatin to sandostatin: Pharmacodynamics and pharmacokinetics. Metab Clin Exp 1992; 4:7-10
18. Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-Independent docetaxel-resistant prostate cancer: Experimental data. BJU Int 2008; 102:622-627
19. Dimopoulos MA, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: A randomized phase II study. Urology 2004; 63:120-125
20. Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, et al. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases. Clin Cancer Res 2004; 10:4398-4405
21. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006; 17:1733-1742
22. Lonowski A, Schally AV, Nagy A, Sun B, Szepeshazi K. Inhibition of PC-3 human androgen-Independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238. Cancer Res 1999; 59: 1947-1953
23. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS-201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31:1133-1140
24. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-Activated protein kinase-Induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004; 64:6190-6199
25. Tang X, Takekoshi S, Itoh J, Umemura S, Shoji S, Terachi T, et al. Somatostatin analogue inhibits the mobility of prostate carcinoma cells: A new therapeutic method for advanced prostate carcinoma. Int J Oncol 2010; 37:1077-1083
26. Hua YP, Yin XY, Peng BG, Li SQ, Lai JM, Liang HZ, et al. Mechanisms and influence of octreotide-Induced regulation of somatostatin receptor 2 on hepatocellular carcinoma. Chemotherapy 2009; 55:312-320
27. Erten C, Karaca B, Kucukzeybek Y, Gorumlu G, Cengiz E, Gul MK, et al. Regulation of growth factors in hormone- And drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int 2009; 104:107-114
28. Sui C, Ma Q, Nan K, Xiao J, Suo A, Sha H, et al. hSSTR2 expression and octreotide treatment reverses multidrug resistance of BxPC-3 human pancreatic cancer cells. Oncol Rep 2009; 22:1391-1396
29. Horiguchi K, Yamada M, Satoh T, Hashimoto K, Hirato J, Tosaka M, et al. Transcriptional activation of the mixed lineage leukemia-p27Kip1 pathway by a somatostatin analogue. Clin Cancer Res 2009; 15:2620-2629
30. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, et al. The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 2010; 70:666-674
31. Pages P, Benali N, Saint-Laurent N, Estè ve JP, Schally AV, Tkaczuk J, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem 1999; 274: 15186-15193
32. Tsagarakis NJ, Drygiannakis I, Batistakis AG, Kolios G, Kouroumalis EA. Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. World J Gastroenterol 2011; 17:313-321